P&G Health and medical experts share clinical guidance in
the diagnosis and treatment of nerve damage among diabetic
patients
MANILA, Philippines,
Nov. 11, 2022 /PRNewswire/ -- Ahead
of World Diabetes Day 2022, P&G Health, brought together
globally renowned multidisciplinary medical experts with Healthcare
Professionals from across Asia-Pacific and the Middle East, at the 'Winning the Fight
Against Neuropathy in Diabetic Patients' forum to share the
latest clinical guidance on diagnosing and treating diabetic nerve
damage. Hosted out of Manila and
simulcast to more than 10 countries and 3400 participants, the
signature event saw the roll out of clinical guidance on simple
diagnostic procedure for peripheral neuropathy and sharing of
clinical experiences by medical experts.
With Diabetes Mellitus being the leading cause[1] of
peripheral neuropathy (PN), the increasing prevalence of PN is
closely linked to the rise in the number of diabetic patients. PN
including Diabetic Peripheral Neuropathy (DPN) is the result of
damage to the nerves impacting quality of life of people as they
are not able to go about their daily lives as comfortably. Burning
and stabbing pain in the feet and hands can have a significant
impact on the activities of daily living, including walking,
climbing stairs, and sleeping. Peripheral neuropathy is often
misdiagnosed or underdiagnosed due to a lack of awareness amongst
both patients and physicians[2]. Besides diabetes
mellitus, B vitamins deficiencies and aging are other high-risk
factors leading to peripheral nerve damage.
Dr Ashley Barlow,
Senior Director, Medical & Technical Affairs, P&G
Health (Asia Pacific,
India, Middle East, and Africa) shared, "As a partner to
International Diabetes Federation (IDF), P&G Health is
committed to continued efforts to raise awareness on Diabetes and
its associated complications including Peripheral Neuropathy and
Nerve Damage. The 'Winning the Fight Against Neuropathy in Diabetic
Patients' forum is the first of several scientific forums being
rolled out by P&G Health as part of our World Diabetes Day
awareness efforts across Asia
Pacific, Middle East, and
Africa region, to highlight the
connection between Peripheral Neuropathy and Diabetes and the
importance of early identification and timely treatment."
Speaking at the forum, Dr. Rayaz A.
Malik (Professor of Medicine at Weill
Cornell Medicine, Consultant Physician at Central Manchester
University Teaching Hospital) shared,
"Peripheral neuropathy is highly underdiagnosed in
South-East Asia and the Middle
East due to a lack of consensus guidance on routine screening
and diagnostic pathways. This has a major impact on the
quality of life as a result of painful neuropathic
symptoms, foot ulceration and amputation with an
associated 5-year mortality of 40% and 80%, respectively.
An awareness and sense of urgency amongst patients and
healthcare providers is required, and primary care physicians need
simple tools and guidance to help them diagnose peripheral
neuropathy."
The P&G Health 'Winning the Fight Against Neuropathy in
Diabetic Patients' forum brought to light enriching insights,
data and clinical practice guidelines from health experts from
across the globe and the region on the important role of neuropathy
diagnoses, treatment and management, in improving the quality of
life of diabetic patients," added Dr. Ashley Barlow.
"While identifying a patient with early onset PN may sound
challenging, it is not and doesn't require complex diagnostic tools
to diagnose peripheral neuropathy. Simple tools like a
questionnaire and a sensory test can be a good start. By
asking the right questions and listening to the patient, we can
help patients avoid severe complications and improve their
quality of life. The primary care physician has a key role to play
in this," added Dr. Rayaz A Malik.
For more information on the 'Winning the Fight Against
Neuropathy in Diabetic Patients' forum, click here to register and
learn from the webinar as healthcare professional:
WDDglobalwebinar
FAST FACTS
- In 2021, there were 393 million diabetic patients in the
Asia Pacific, the Middle East, and African regions projected to
rise to 603 million by 2045[3].
- 1 in 2 patients with diabetes and suffer from Peripheral
Neuropathy[4] during their lifetime. With the increasing
prevalence of diabetes there will be an exponential growth in the
number of patients in these regions with PN.
- There are also at least as many people with pre-diabetes
as there are with diabetes and at least 10% suffer from
PN[5].
- A study from the
Philippines in 2000 from the Diabcare-Asia project, which
assessed 2,708 patients in diabetes centres, reported a prevalence
of 42% for diabetic neuropathy, based on medical
records[6].
- < 1/3rd of physicians recognize signs of DPN.
Undiagnosed cases contributing greatly to the high rates of
morbidity and mortality of diabetes[3]. Up to 50 % of
patients are asymptomatic and therefore often remain undiagnosed
and are at risk of insensate injury[7].
- If not diagnosed and treated early, DPN can manifest with
neuropathic pain with a tremendous impact on the quality of
life.
About P&G Health: P&G Health, the health care
division of P&G company, drives consumer-centric innovation to
empower our consumers to live healthier, and more vibrant lives.
The P&G Health portfolio includes leading brands in Respiratory
with Vicks® and Nasivin®, Pregnancy with Femibion® and Clearblue®,
Oral Care with Crest® and Oral-B®, Vitamins and Minerals
Supplementation with Bion3®, Seven Seas®, Evion® and Sangobion®,
Digestive wellness with Metamucil®, Prilosec OTC®, Pepto Bismol®
and Align®, Nerve Care with Neurobion® and Pain Relief with
Dolo-Neurobion®.
About Procter & Gamble: P&G serves consumers
around the world with one of the strongest portfolios of trusted,
quality, leadership brands, including Always®, Ambi Pur®, Ariel®,
Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®,
Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®,
Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G
community includes operations in approximately 70 countries
worldwide.
References:
- Landmann G. Ars Medici. 2013;1: 18-21
- Malik, Rayaz et. al. Journal of Diabetes Investigation. 11.
10.1111/jdi.13269.
- International Diabetes Federation. IDF Diabetes Atlas. 10th
edition; 2021.
- Kumar S, et al. Laser Therapy 2016;25: 141–144
- Kirthi V et. al. BMJ Open Diabetes Res Care. 2021
May;9(1):e002040
- Lantion-Ang LC. Diabetes Res Clin Pract 2000; 50 (Suppl 2):
S29–S34.
- Miranda-Massari JR, et al. Curr Clin Pharmacol.
2011;6: 260–273.
Photo - https://mma.prnewswire.com/media/1944556/PG2.jpg
Photo - https://mma.prnewswire.com/media/1944555/PG1.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/winning-the-fight-against-neuropathy-in-diabetic-patients-301675417.html